Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM
Type 2 Diabetes Mellitus

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Is at least 25 years old at Visit 1 (Screening).
Is male, or is female and meets all of the following criteria:
- Not breastfeeding
- Negative pregnancy test result at Visit 1 (not applicable to post-menopausal or surgically sterile females)
- Surgically sterile, postmenopausal, or if of childbearing potential, must practice and be willing to continue to practice appropriate birth control during the entire duration of the study.
- Body mass index (BMI) 20.0 to 45.0 kg/m² (inclusive) at Visit 1 (Screening).
- Has a physical examination with no clinically significant abnormalities as judged by the investigator.
- Has T2DM and an HbA1c of 7.5% to 10.5%, inclusive, at Visit 1.
- Has an estimated glomerular filtration rate (eGFR) value of ≥60 mL/min/1.73 m² based on the Modification of Diet in Renal Disease (MDRD) equation.
Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 3 months prior to Visit 1:
- Thiazolidinedione, sulfonylurea, dipeptidyl peptidase-4 inhibitors, and alpha-glucosidase inhibitors
- Hormone replacement therapy (female subjects) and testosterone (male subjects)
- Oral contraceptives (female subjects)
- Antihypertensive agents
- Lipid-lowering agents
- Thyroid replacement therapy
- Antidepressant agents
- Ability to understand and willingness to adhere to protocol requirements.
Exclusion Criteria:
Has a clinically significant medical condition as judged by the investigator that could potentially affect study participation and/or personal well-being, including but not limited to the following conditions:
- Hepatic disease
- Gastrointestinal disease
- Endocrine disorder (T2DM is allowed)
- Cardiovascular disease
- Central nervous system diseases
- Psychiatric or neurological disorders
- Organ transplantation
- Chronic or acute infection
- Orthostatic hypotension, fainting spells or blackouts
- Allergy or hypersensitivity.
- A history of diabetic ketoacidosis or hyperosmolar non-ketotic hyperglycemia within the past year.
- Prior major surgery of any kind within 6 months of Visit 1.
- A history of >3% weight change within 3 months of Visit 1.
- A clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormality, other than that related to T2DM, judged by the investigator to be clinically significant at Visit 1.
- An alanine aminotransferase or aspartate aminotransferase result >2.5 × upper limit of normal (ULN) or a bilirubin result >1.5 × ULN.
- A physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study.
Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following excluded medications:
- Metformin within 2 months of Visit 1 (Screening)
- Insulin within 2 weeks of Visit 1 (Screening) or for more than 1 week within 3 months of Visit 1 (Screening)
- Glucagon-like peptide-1 receptor agonists or sodium-glucose co-transporter 2 inhibitors within 3 months of Visit 1
- Drugs known to affect body weight, including prescription medications and over-the-counter anti obesity agents within 3 months of Visit 1.
- Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption within 3 months of Visit 1
- Planned use of any drug treatment that affects gastric pH (prescription or over-the-counter), such as H2-receptor antagonists and proton pump inhibitors, after Visit 2 (Week -2), or planned chronic use of any antacids (i.e., more than twice per week) after Visit 2 (Week -2)
- Cationic drugs that are eliminated by renal tubular secretion within 1 week of Visit 1.
- Iodinated contrast dye within 1 week prior to Visit 1.
- Investigational drug within 2 months (or five half-lives of the investigational drug, whichever is greater) of the date of the first dose of randomized study medication.
- Met DR or double-blind matching placebo for Met DR at any time prior to Visit 1 (Screening)
- Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures.
- Had a blood transfusion or experienced significant blood loss (i.e., >500 mL), including loss due to blood donation, within 2 months prior to Visit 1 (Screening), or is planning to donate blood during the study.
- Has known immune system based allergies or hypersensitivity to any component of study treatment. A history of gastrointestinal intolerance to metformin is not exclusionary.
- Is employed by Elcelyx Therapeutics, Inc. (that is an employee, contract worker, or designee of the company).
- Has a fasting plasma glucose value >270 mg/dL at Visit 1 (Screening), Visit 2 (Week -2), and an unscheduled visit to be completed within 1 week following Visit 2. The unscheduled visit is to be completed only for subjects with a fasting plasma glucose value >270 mg/dL at Visit 1 and Visit 2.
Sites / Locations
- Pinnacle Research Group, LLC
- Central Alabama Research
- Achieve Clinical Research, LLC
- University of Alabama at Birmingham
- Terence T. Hart, MD
- Radiant Research - Phoenix
- Arrowhead Health Centers
- Holland Center for Family Health, LTD
- Elite Clinical Studies
- Thunderbird Internal Medicine - Indian School Rd.
- Clinical Research Institute of Arizona, LLC
- Summit Clinical Trials Center
- Searcy Medical Center
- Advanced Metabolic Care & Research Institute (AMCR)
- MD Studies, Inc.
- National Research Institute
- Scripps Whittier Diabetes Institute
- Clinical Trials Research
- Collaborative Neuroscience Network, LLC
- National Research Institute
- Catalina Research Institute
- SRSD, Inc. dba Synergy San Diego
- Providence Clinical Research
- Pacific Research Partners, LLC
- SDS Clinical Trials, Inc.
- Center for Clinical Trials of Sacramento
- Center for Clinical Trials of Scaramento
- Superior Research LLC
- Syrentis Clinical Research (formerly Research Across America)
- Encompass Clinical Research
- Clinical Trial Investigators
- Infosphere Clinical Research
- Colorado Springs Health Partners
- Creekside Endocrine Associates
- Meridien Research - Brooksville
- ALL Medical Research, LLC
- Neostart Corporation dba AGA Clinical Trials
- Care Partners Clinical Research
- Health Awareness, Inc.
- Family Health Care Clinical Studies
- Clinical Research of Central Florida-Lakeland
- Clinical Pharmacology of Miami, Inc.
- Tellus Clinical Research, Inc.
- Internal Research Associates LLC - Breton
- Clinical Neuroscience Solutions, Inc. Healthcare Orlando
- Ormond Medical Arts Pharmaceutical Research Center
- Private Practice - Andres Patron, DO
- Progressive Medical Research
- Meridien Reserach - St. Petersburg
- Clinical Reserch Trials of Florida
- Meridien Research - Tampa
- Metabolic Research Institute, Inc.
- Biofortis, Inc.
- AMR Sakeena Research
- Cedar-Crosse Research Center
- Evanston Premier Healthcare Research LLC
- Buynak Clinical Research, PC
- The Iowa Clinic; Cardiovascular Services
- Heartland Research Associates, LLC - Augusta
- Cotton-O'Neil Clinical Research Center
- Otrimed
- Kentucky Diabetes Endocrinology Center
- Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
- Four Rivers Clinical Research
- Avant Research Associates
- Centex Studies, Inc. - lake Charles
- Columbia Medical Practice
- Medstar Health Research Institute
- MD Medical Research
- Beacon Clinical Research
- Radiant Research - Edina
- Planters Clinic
- Mercury Street Medical Group, PLLC
- Quality Clinical Research, Inc.
- Heartland Clinical Research
- Alliance Against Diabetes
- AB Clinical Trials
- Palm Medical Research
- Ingham Neuroscience Group, LLC
- Comprehensive Clinical Research
- Albuquerque Clinical Trials
- Albuquerque Neuroscience, Inc.
- NY Scientific
- Long Island Gastrointestinal Research Group
- Mid-Hudson Medical Research, PLLC
- Great Lakes Medical Research
- PharmQuest
- Triad Clinical Trials LLC
- PMG Research of Rocky Mount
- PMG Research of Salisbury, LLC
- PMG Research of Wilmington, LLC
- Sterling Research Group, Ltd
- Metabolic Atherosclerosis Research Center
- New Horizons Clinical Research
- Urgent Care Specialists, LLC DBA Hometown Urgent Care and Occupational Health
- Prestige Clinical Research
- Hometown Urgent Care and Research - Huber Heights
- RAS Health LTD
- Summit Reserach Group, LLC
- COR Clinical Research, LLC
- Willamette Valley Clinical Studies
- Brandywine Clinical Research
- Medical Research South, LLC
- Mountain View Clinical Research - Greer
- PMG of Charleston, LLC
- Family Medicine of SayeBrook, LLC
- Hillcrest Clinical Research, LLC
- Palmetto Proactive Healthcare, LLC
- Spartanburg Medical Research
- Palmetto Clinical Research
- PMG Research of Bristol, LC - State
- PMG Research of Knoxville
- Clinical Neuroscience Solutions, Inc. - Memphis
- Trinity Clinical Research
- Central Texas Clinical Research
- Trinity Universal Research Associates, Inc.
- Dallas Diabetes and Endocrine Center
- Research Institute of Dallas
- Galenos Research
- Pioneer Research Solutions, Inc.
- Centex Studies, Inc.
- Clinical Trial Network - Houston
- Juno Research, LLC-Houston
- Juno Research, LLC-Katy
- Texas Diabetes Institute Research Center
- Sun Research Institute
- Victorium Clinical Research
- Consano Clinical Research
- Southwest Health Associates, P.A.
- Chrysalis Clinical Research
- Burke Internal Medicine & Research
- Manassas Clinical Research Center
- Clinical Research Partners, LLC
- Universal Research Group, LLC
- Puerto Rico Renal and Health Research, Inc.
- Advanced Medical Concepts
- Manati Center for Clinical Reserach Doctor's Center Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Experimental
Experimental
Experimental
Experimental
Placebo Comparator
Placebo Comparator
Active Comparator
600 mg Met DR qAM
900 mg Met DR qAM
1200 mg Met DR qAM
1500 mg Met DR qAM
Placebo-1
Placebo-2
2000 mg Met IR
600 mg metformin delayed-release once daily in the morning
900 mg metformin delayed-release once daily in the morning
1200 mg metformin delayed-release once daily in the morning
1500 mg metformin delayed-release once daily in the morning
placebo match for 600 and 1200 mg Met DR qAM treatment groups
placebo match for 900 and 1500 mg Met DR qAM treatment groups
1000 mg metformin immediate-release twice daily